secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000886744-25-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron Q2 net product revenue $49.0M, net loss narrows to $16.4M; new CEO named
------------------------------------------------------------------------------

- Net product revenue of $49.0M from RYTELO in Q2 2025, up 24% QoQ; demand up 17% QoQ with over 1,000 ordering accounts.
- Net loss of $16.4M ($0.02/share) vs $67.4M loss ($0.10) in Q2 2024, driven by rising RYTELO sales and lower R&D costs.
- Phase 3 IMpactMF trial in myelofibrosis now over 95% enrolled; full enrollment expected by year-end 2025.
- Harout Semerjian appointed President and CEO; seasoned commercial hematology and oncology leader.
- FY2025 operating expense guidance maintained at $270M-285M; cash and securities $432.6M as of June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/0000886744-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000886744-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer